90-Second Read: New Hantavirus antibody and vaccine work targets severe lung syndrome

Rapid Andes virus antibody and vaccine work anchors a Dyadic, Scripps pact using the C1 platform to accelerate biologic production for future outbreaks. Dyadic (NASDAQ: DYAI) and Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting Hantaviruses, including Andes virus linked to Hantavirus Pulmonary Syndrome. This announcement highlights Dyadic's C1 platform being used with Scripps Research to develop Hantavirus antibodies and vaccines, building on prior work in Andes virus, Ebola, and Marburg. Partnership headlines have often seen weak or negative next-day reactions, with 3 of 4 prior events closing lower despite strategically positive announcements.

Today's Scripps Research collaboration continues this pattern of leveraging external partners to validate the C1 platform and expand its use in vaccines and monoclonal antibodies. Partnership headlines over the past several events averaged a -3.25% next-day move, even though the deals, like today's Scripps collaboration, emphasized strategic expansion of Dyadic's C1 platform. Partnerships have progressed from albumin and media proteins toward broader research-use proteins and now infectious-disease antibodies and vaccines on the C1 platform. Historically, partnerships have been central to expanding C1 into albumin, enzymes, and growth factors, though share reactions have been mixed with an average move of -3.25%.

The work uses Dyadic's fungal-based C1 platform for rapid, scalable biologic production to support future infectious disease preparedness. The collaboration builds on prior Andes, Ebola and Marburg research, preclinical data showing C1-produced antibodies with comparable binding and neutralization to mammalian systems, and funded programs with the Gates Foundation, CEPI, FBS and EU initiatives. DYAI was up about 0.65% while close peers like CASI ( -38.97% ) and LSB ( -20.62% ) were sharply lower, indicating the collaboration headline was company-specific rather than part of a sector-wide move. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic's control.

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic's C1 Platform Capabilities for Fast, Scalable Biologic Production JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. Dyadic recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets. Together, these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines, scalable microbial fermentation, and streamlined manufacturing processes.